Stay updated on TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page.

Latest updates to the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedFooter now shows Revision: v3.3.3; the previous Revision: v3.3.2 and the HHS Vulnerability Disclosure link have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check41 days agoChange DetectedMinor textual clarifications: publications are automatically filled from PubMed and may not be about the study; revision updated to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe government funding/operating status notice was removed from the page. The core study details, eligibility criteria, and study status remain unaffected.SummaryDifference0.4%

- Check62 days agoChange DetectedNo significant additions or deletions were detected; the study details and core information remain unchanged, with any observed differences likely cosmetic or layout adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check91 days agoChange DetectedUpdate includes a critical operating status notice and a new software revision tag (v3.2.0), indicating updated deployment with current status information.SummaryDifference3%

- Check98 days agoChange DetectedVersion metadata updated from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TIL and Anti-PD1 in Metastatic Melanoma Clinical Trial page.